Morgan Stanley Maintains Overweight on CinCor Pharma, Raises Price Target to $45
Morgan Stanley analyst Jeffrey Hung maintains CinCor Pharma (NASDAQ:CINC) with a Overweight and raises the price target from $31 to $45.
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.
Nasdaq Turns Lower; Crude Oil Rises Over 1%
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.
Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…
Twitter Shares Surge Around 8%, Here’s 66 Biggest Movers From Yesterday
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
Twitter, Delta Air Lines And 45 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 122.4% to $6.76. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th.
63 Biggest Movers From Yesterday
Gainers
Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
CinCor Pharma Doses First Patient In Phase 2 FigHTN-CKD Trial Evaluating The Selective Aldosterone Synthase Inhibitor Baxdrostat In Patients With Uncontrolled Hypertension And Chronic Kidney Disease
CinCor Pharma, Inc. (“CinCor”) announced today that the first patient has been dosed in the Phase 2 figHTN-CKD trial evaluating baxdrostat (CIN-107), a highly selective aldosterone synthase inhibitor, in
